Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy

NCT01313117 | Completed Phase 1 Results DMC

• 1 other identifier: NUALA-01
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

This study is being done because peripheral neuropathy, a condition that interrupts sensation in your limbs, is a common side effect of paclitaxel. There is some evidence that alpha lipoic acid (ALA), an antioxidant compound, protects neurons after exposure to paclitaxel. The purpose of this study is to assess the safety and tolerability of ALA and to find the best dose of ALA in patients that receive chemotherapy.

Conditions

Peripheral Neuropathy

Keywords

chemotherapy; peripheral neuropathy; paclitaxel; breast cancer

Outcome Measures

Primary Outcomes (1)

• Identification of the Optimal Dose of ALA Based on Acceptable Adverse Event(AE) Profile

  Based on acceptable adverse event (AE) profile and continual reassessment method dose escalation.

  4 months

Secondary Outcomes (3)

• Proportion of Patients Who Complete the Proposed Regimen of Daily ALA

  4 months

• Cumulative Rate of Adverse Events

  4 months

• Total Neuropathy Score (TNS)

  4 months

Study Arms (1)

Alpha lipoic acid

EXPERIMENTAL

Oral administration three times daily (morning, mid-day, night)

Drug: Alpha lipoic acid

Interventions

Alpha lipoic acid DRUG

The baseline dose is 100 mg three times daily for four months. Dose escalation will occur until a maximum tolerated dose is found.

Also known as: Thioctic Acid

Alpha lipoic acid

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of Breast cancer.
• Breast cancer must meet the following criteria:
• Early stage breast cancer (stages I, IIA) must be estrogen receptor (ER) positive AND low tumor grade (histopathologic grade 1 or 2)
• Locally advanced breast cancer (LABC) (stages IIB, IIIA, IIB as defined by the Union for International Cancer Control and American Joint Committee on Cancer) must be ER positive, HER2 positive or HER2 negative, AND satisfy the following requirements: high endocrine responsiveness (defined as greater than 50% of tumor cells staining for hormone receptors), Grade 1 or 2 histological grade, less than 4 nodes positive, absence of extensive peritumoral vascular invasion, AND pathological tumor size less than 5 cm.
• Inflammatory breast cancer (IBC) (stage IIIC)
• Metastatic breast cancer (stage IV)
• Must be receiving single agent paclitaxel in their prescribed chemotherapy regimen.
• Age \> 18 years. There is no upper age limit for participation in this study.
• Required lab values: AST, ALT, creatinine
• Women of childbearing potential and sexually active males must agree to use contraception while on study.
• ECOG performance status 0,1,2
• All patients must have given signed, informed consent.

You may not qualify if:

• Breast cancer meeting the following criteria:
• Breast cancer stage 0
• Early stage breast cancer (stages I, IIA) that is ER negative OR higher tumor grade (histopathologic grade greater than 2)
• Stages I, II, and IIIA triple negative breast cancer (negative for estrogen receptors, progesterone receptors, and HER2)
• LABC (stages IIB, IIIA, IIB) if they have low endocrine responsiveness (defined as less than 50% of tumor cells staining for hormone receptors), Grade 3 histological grade, 4 or more nodes positive, presence of extensive peritumoral vascular invasion, OR pathological tumor size greater than 5 cm
• LABC (stages IIB, IIIA, IIB) that are ER negative
• Evidence of pre-existing peripheral neuropathy as determined by baseline Michigan neuropathy screening instrument score \> 2.
• Previous chemotherapy treatment of any kind.
• AST and ALT \>2 times upper limit of normal; Creatinine \> 2.0 mg/dL.
• Current use of medications or substances known to be associated with peripheral neuropathy.
• Use of ALA or other anti-oxidant supplements during the prior three months.
• Diabetes mellitus or use of medications known to lower blood sugar.
• Participation in any other experimental trial.

Sponsors & Collaborators

• Northwestern University: lead

Study Sites (1)

Northwestern Medical Faculty Foundation

Chicago, Illinois, 60611, United States

Location

Related Publications (13)

• Siau C, Xiao W, Bennett GJ. Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol. 2006 Oct;201(2):507-14. doi: 10.1016/j.expneurol.2006.05.007. Epub 2006 Jun 22.

  PMID: 16797537 BACKGROUND

• McCarty MF, Barroso-Aranda J, Contreras F. The "rejuvenatory" impact of lipoic acid on mitochondrial function in aging rats may reflect induction and activation of PPAR-gamma coactivator-1alpha. Med Hypotheses. 2009 Jan;72(1):29-33. doi: 10.1016/j.mehy.2008.07.043. Epub 2008 Sep 11.

  PMID: 18789599 BACKGROUND

• Melli G, Taiana M, Camozzi F, Triolo D, Podini P, Quattrini A, Taroni F, Lauria G. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol. 2008 Dec;214(2):276-84. doi: 10.1016/j.expneurol.2008.08.013. Epub 2008 Sep 9.

  PMID: 18809400 BACKGROUND

• Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006 Nov;29(11):2365-70. doi: 10.2337/dc06-1216.

  PMID: 17065669 BACKGROUND

• Cremer DR, Rabeler R, Roberts A, Lynch B. Safety evaluation of alpha-lipoic acid (ALA). Regul Toxicol Pharmacol. 2006 Oct;46(1):29-41. doi: 10.1016/j.yrtph.2006.06.004. Epub 2006 Aug 14.

  PMID: 16904799 BACKGROUND

• Segermann J, Hotze A, Ulrich H, Rao GS. Effect of alpha-lipoic acid on the peripheral conversion of thyroxine to triiodothyronine and on serum lipid-, protein- and glucose levels. Arzneimittelforschung. 1991 Dec;41(12):1294-8.

  PMID: 1815532 BACKGROUND

• GAL EM, RAZEVSKA DE. Studies on the in vivo metabolism of lipoic acid. 1. The fate of DL-lipoic acid-S35 in normal and thiamine-deficient rats. Arch Biochem Biophys. 1960 Aug;89:253-61. doi: 10.1016/0003-9861(60)90051-5. No abstract available.

  PMID: 13825981 BACKGROUND

• Cremer DR, Rabeler R, Roberts A, Lynch B. Long-term safety of alpha-lipoic acid (ALA) consumption: A 2-year study. Regul Toxicol Pharmacol. 2006 Dec;46(3):193-201. doi: 10.1016/j.yrtph.2006.06.003. Epub 2006 Aug 8.

  PMID: 16899332 BACKGROUND

• Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schutte K, Gries FA. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995 Dec;38(12):1425-33. doi: 10.1007/BF00400603.

  PMID: 8786016 BACKGROUND

• Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Moller W, Tritschler HJ, Mehnert H. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res. 1999 Sep;31(3):171-9. doi: 10.1080/10715769900300721.

  PMID: 10499773 BACKGROUND

• Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schutte K, Kerum G, Malessa R. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999 Aug;22(8):1296-301. doi: 10.2337/diacare.22.8.1296.

  PMID: 10480774 BACKGROUND

• Ruhnau KJ, Meissner HP, Finn JR, Reljanovic M, Lobisch M, Schutte K, Nehrdich D, Tritschler HJ, Mehnert H, Ziegler D. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999 Dec;16(12):1040-3. doi: 10.1046/j.1464-5491.1999.00190.x.

  PMID: 10656234 BACKGROUND

• Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O'Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D; SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003 Mar;26(3):770-6. doi: 10.2337/diacare.26.3.770.

  PMID: 12610036 BACKGROUND

MeSH Terms

Conditions

Peripheral Nervous System Diseases; Breast Neoplasms

Interventions

Thioctic Acid

Condition Hierarchy (Ancestors)

Neuromuscular Diseases; Nervous System Diseases; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Carboxylic Acids; Organic Chemicals; Thiophenes; Sulfur Compounds; Coenzymes; Enzymes and Coenzymes; Fatty Acids; Lipids

Limitations and Caveats

The small number of enrolled patients precluded any meaningful ALA dose finding or neuropathy prevention efficacy statements. A formal statistical analysis of the data was not able to be performed.

Results Point of Contact

• Title: Jeffrey Allen M.D.
• Organization: Northwestern University

jallen1@nmff.org

312-695-8636

Study Officials

• Jeffrey A. Allen, MD

  Northwestern University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor in Ken and Ruth Davee Department of Neurology

Study Record Dates

• First Submitted: March 9, 2011
• First Posted: March 11, 2011
• Study Start: February 1, 2012
• Primary Completion: August 1, 2013
• Study Completion: January 1, 2014
• Last Updated: October 2, 2014
• Results First Posted: October 2, 2014

Record last verified: 2014-09

Locations

US (1)